Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Feb 21 04:00PM ET
48.13
Dollar change
-1.37
Percentage change
-2.77
%
IndexRUT P/E- EPS (ttm)-0.22 Insider Own0.73% Shs Outstand47.72M Perf Week4.74%
Market Cap2.30B Forward P/E395.25 EPS next Y0.12 Insider Trans-31.41% Shs Float47.37M Perf Month14.51%
Income-10.25M PEG- EPS next Q0.17 Inst Own109.39% Short Float3.66% Perf Quarter31.57%
Sales185.21M P/S12.40 EPS this Y54.43% Inst Trans-1.99% Short Ratio3.29 Perf Half Y48.64%
Book/sh4.29 P/B11.23 EPS next Y176.34% ROA-3.62% Short Interest1.73M Perf Year61.40%
Cash/sh2.69 P/C17.88 EPS next 5Y- ROE-5.37% 52W Range27.92 - 50.09 Perf YTD35.16%
Dividend Est.- P/FCF121.52 EPS past 5Y7.38% ROI-3.63% 52W High-3.91% Beta1.72
Dividend TTM- Quick Ratio4.83 Sales past 5Y16.52% Gross Margin67.66% 52W Low72.39% ATR (14)1.81
Dividend Ex-Date- Current Ratio5.18 EPS Y/Y TTM43.94% Oper. Margin-7.08% RSI (14)65.46 Volatility3.52% 3.91%
Employees305 Debt/Eq0.42 Sales Y/Y TTM16.30% Profit Margin-5.54% Recom1.00 Target Price47.40
Option/ShortYes / Yes LT Debt/Eq0.38 EPS Q/Q44.91% Payout- Rel Volume1.17 Prev Close49.50
Sales Surprise0.97% EPS Surprise33.99% Sales Q/Q18.24% EarningsFeb 29 BMO Avg Volume526.48K Price48.13
SMA206.97% SMA5021.49% SMA20034.40% Trades Volume616,683 Change-2.77%
Date Action Analyst Rating Change Price Target Change
Jan-25-24Upgrade Truist Hold → Buy $39 → $51
Aug-08-23Upgrade BTIG Research Neutral → Buy $39
Nov-10-22Downgrade BTIG Research Buy → Neutral
Nov-09-22Downgrade Truist Buy → Hold
Oct-14-22Resumed Stephens Overweight $40
Jan-11-21Downgrade Oppenheimer Outperform → Perform
Dec-18-20Initiated Stephens Overweight $31
Sep-17-20Initiated Truist Buy $24
Oct-09-19Initiated H.C. Wainwright Buy $19
Feb-28-19Downgrade Needham Buy → Hold
Feb-18-24 03:00AM
Feb-15-24 10:00AM
08:50AM
08:30AM
Feb-05-24 08:30AM
11:01PM Loading…
Jan-30-24 11:01PM
08:50AM
Jan-25-24 09:49AM
Jan-24-24 07:01PM
Jan-19-24 08:28PM
Jan-09-24 08:47AM
07:55AM
Jan-03-24 08:30AM
Dec-17-23 03:01AM
Dec-09-23 03:05AM
05:04AM Loading…
Dec-02-23 05:04AM
Nov-23-23 07:04AM
Nov-16-23 05:35PM
Nov-10-23 09:52PM
Nov-09-23 03:56PM
Nov-08-23 03:30PM
07:55AM
Nov-07-23 08:30AM
Nov-01-23 10:01AM
Oct-25-23 08:30AM
Oct-24-23 01:22AM
Oct-23-23 05:59PM
Oct-16-23 10:23AM
Sep-28-23 08:30AM
Sep-20-23 04:30PM
08:30AM Loading…
Sep-06-23 08:30AM
Aug-10-23 01:48AM
Aug-02-23 09:05AM
07:55AM
Jul-23-23 11:44AM
Jul-20-23 08:30AM
Jul-10-23 09:30AM
Jun-21-23 08:00PM
May-10-23 09:05AM
07:55AM
May-02-23 09:00AM
Apr-26-23 08:00PM
08:30AM
Apr-24-23 02:06AM
Apr-17-23 03:03PM
Feb-28-23 08:30AM
Feb-23-23 09:45AM
07:55AM
Feb-09-23 08:00AM
Jan-31-23 07:19AM
Jan-11-23 10:24PM
Jan-10-23 07:55AM
Jan-04-23 08:34AM
Dec-30-22 01:42PM
05:26AM
Dec-29-22 01:46PM
01:45PM
Nov-11-22 06:09AM
Nov-10-22 09:00AM
Nov-09-22 09:05AM
07:55AM
Oct-26-22 08:30AM
Oct-10-22 11:50AM
Sep-22-22 08:30AM
Sep-06-22 08:30AM
Aug-09-22 09:55AM
Aug-04-22 04:30AM
Aug-03-22 09:05AM
07:55AM
07:30AM
Jul-21-22 04:05PM
Jul-20-22 08:30AM
Jul-08-22 08:30AM
Jun-30-22 10:50AM
May-04-22 08:30PM
09:05AM
07:55AM
Apr-20-22 08:30AM
Apr-09-22 08:07AM
Mar-15-22 08:30AM
Mar-01-22 08:30AM
Feb-24-22 06:30PM
04:45PM
09:15AM
07:55AM
Feb-17-22 03:02PM
Feb-10-22 09:00AM
Feb-02-22 04:05PM
Jan-25-22 09:38PM
Jan-04-22 08:30AM
Dec-17-21 11:38AM
Dec-13-21 04:38PM
Nov-11-21 08:30AM
Nov-09-21 08:01PM
08:55AM
07:40AM
Nov-02-21 03:02PM
Oct-29-21 11:11AM
Oct-21-21 08:30AM
Oct-13-21 06:25AM
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Colangelo DominickPresident and CEOFeb 15Option Exercise3.0217,50052,850191,508Feb 16 04:05 PM
Colangelo DominickPresident and CEOFeb 15Sale48.8517,500854,875174,008Feb 16 04:05 PM
Colangelo DominickPresident and CEOFeb 14Option Exercise3.0217,50052,850191,508Feb 16 04:05 PM
Colangelo DominickPresident and CEOFeb 14Sale46.9917,500822,325174,008Feb 16 04:05 PM
Colangelo DominickPresident and CEOFeb 12Option Exercise0.007,5000177,485Feb 13 04:05 PM
Halpin MichaelChief Operating OfficerFeb 12Option Exercise0.003,50004,449Feb 13 04:05 PM
Hopper Jonathan MarkChief Medical OfficerFeb 12Option Exercise0.001,625054,759Feb 13 04:06 PM
ZERBE ROBERT L MDDirectorJan 29Sale44.222,300101,70623,395Jan 30 04:05 PM
ZERBE ROBERT L MDDirectorJan 25Sale44.022008,80425,695Jan 29 04:05 PM
ZERBE ROBERT L MDDirectorJan 22Option Exercise4.123,00012,36028,895Jan 24 04:05 PM
ZERBE ROBERT L MDDirectorJan 22Sale41.858,000334,77525,895Jan 24 04:05 PM
Colangelo DominickPresident and CEOJan 18Option Exercise3.0216,72650,513186,711Jan 19 04:06 PM
Colangelo DominickPresident and CEOJan 18Sale38.5816,726645,289169,985Jan 19 04:06 PM
Colangelo DominickPresident and CEOJan 17Option Exercise3.0216,72650,513186,711Jan 19 04:06 PM
Colangelo DominickPresident and CEOJan 17Sale37.9716,726635,086169,985Jan 19 04:06 PM
ZERBE ROBERT L MDDirectorJan 12Sale38.092,20083,79830,895Jan 16 04:05 PM
Colangelo DominickPresident and CEODec 14Option Exercise3.5712,00042,840181,985Dec 15 04:05 PM
Colangelo DominickPresident and CEODec 14Sale37.1212,000445,440169,985Dec 15 04:05 PM
Wotton Paul KDirectorDec 14Sale37.315,000186,55026,802Dec 15 04:07 PM
Flynn Sean C.SVP, General CounselDec 14Sale37.451063,9704,467Dec 15 04:07 PM
Colangelo DominickPresident and CEODec 13Option Exercise3.5712,00042,840181,985Dec 15 04:05 PM
Colangelo DominickPresident and CEODec 13Sale34.0312,000408,360169,985Dec 15 04:05 PM
Flynn Sean C.SVP, General CounselDec 13Sale34.201,43248,9744,573Dec 15 04:07 PM
Colangelo DominickPresident and CEODec 07Option Exercise3.5712,00042,840188,742Dec 08 04:05 PM
Colangelo DominickPresident and CEODec 07Sale33.8412,000406,080176,742Dec 08 04:05 PM
Colangelo DominickPresident and CEODec 06Option Exercise3.5712,39744,257189,139Dec 08 04:05 PM
Colangelo DominickPresident and CEODec 06Sale34.4312,397426,829176,742Dec 08 04:05 PM
Halpin MichaelChief Operating OfficerNov 30Option Exercise7.2017,447125,61818,274Dec 01 04:05 PM
Halpin MichaelChief Operating OfficerNov 30Sale35.4117,447617,798827Dec 01 04:05 PM
Hopper Jonathan MarkChief Medical OfficerNov 20Option Exercise10.955,00054,75058,007Nov 22 04:05 PM
Hopper Jonathan MarkChief Medical OfficerNov 20Sale36.405,000182,00053,007Nov 22 04:05 PM
SIEGAL JONATHANPrincipal Accounting OfficerNov 15Sale37.7066224,9541,305Nov 17 04:06 PM
ZERBE ROBERT L MDDirectorNov 15Sale38.0230011,40633,095Nov 17 04:06 PM
SIEGAL JONATHANPrincipal Accounting OfficerOct 02Option Exercise0.0093802,134Oct 04 04:05 PM
ZERBE ROBERT L MDDirectorJul 14Sale38.841,00038,84033,395Jul 17 04:05 PM
ZERBE ROBERT L MDDirectorJun 22Sale36.003,000108,00034,395Jun 26 04:05 PM
Rubino Alan LDirectorApr 25Option Exercise10.603,00031,80014,994Apr 27 04:03 PM
ZERBE ROBERT L MDDirectorMar 01Option Exercise10.603,00031,80034,795Mar 03 04:32 PM